• Stavros Aloizos, Efimia Evodia, Stavros Gourgiotis, Eleni-Christina Isaia, Charalampos Seretis, and George J Baltopoulos.
• ICU, 401 General Army Hospital of Athens, Athens, Greece.
• Turk Neurosurg. 2015 Jan 1; 25 (4): 552-8.

AimOur research was focused on the neuroprotective function of erythropoietin (Epo) in patients with severe closed traumatic brain injury (TBI).Material And MethodsOur model examined the influence of the outcome and neurological recovery in 42 adults with TBI who were admitted to ICU within 6 hours of their injury and were recruited into a randomized controlled study of two groups; only the patients of the intervention group received 10,000 i.u. of Epo for 7 consecutive days. A prognostic model based on CRASH II injury model and outcome was measured by survival and Glasgow Outcome Scale-Extended version (GOS-E) score at 6 months post-injury.ResultsSix patients (18.7%) died during the first two weeks; 4 of the control group and 2 of the intervention group. A mortality rate of 22.2% and 8.3% for the control and intervention group respectively was observed. A lower rate of good outcome (GOS-E score > 4) at 6 months was mentioned among patients of the control group.ConclusionThe study provides evidence of lower mortality and better neurological outcome for the patients who received Epo increasing the possibility that Epo therapy could be used in clinical practice, limiting neuronal damage induced by TBI.

43 keywords...

hide…